Edit |   |
---|---|
Antigenic Specificity | CCR2/CD192 (Plozalizumab biosimilar) |
Clone | monoclonal |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG1 kappa |
Format | Protein A/G purified |
Size | 100 µg, 1 mg, |
Concentration | typically between 0.5-2.0 mg/ml. |
Applications | ELISA, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Plozalizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CCR2/CD192, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to sites of inflammation. The recruitment of macrophages to the arterial wall is believed to be a critical step in the development of atherosclerosis. |
Immunogen | n/a |
Other Names | Plozalizumab, CCR2/CD192, 1610761-46-0 |
Gene, Accession # | CAS: 1610761-46-0 |
Catalog # | abx831354 |
Price | please inquire |
Order / More Info | CCR2/CD192 (Plozalizumab biosimilar) Antibody from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950